Evotec achieves first milestones in multi-target deal with UCB

29-Oct-2013 - Germany

Evotec AG announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology.

The milestones were achieved upon the progression of certain projects into hit-to-lead and into lead optimisation.

Dr Mario Polywka, Chief Operating Officer of Evotec, stated: 'We are delighted that the project teams at UCB and Evotec have met these important milestones in the collaboration. The progress in this collaboration is a testament to the way scientists from both companies have worked together in a true partnership.'

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances